<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749383</url>
  </required_header>
  <id_info>
    <org_study_id>TRPV1-SD_IIT</org_study_id>
    <nct_id>NCT02749383</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase II, single center, randomized, double-blind, placebo-controlled study
      in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of
      the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle
      for up to 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success rate in IGE(Investigator's Global Evaluation)</measure>
    <time_frame>Change from Baseline at Day 14 and Day 28</time_frame>
    <description>Treatment success rate in IGE on 28th day from the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Erythema severity score</measure>
    <time_frame>Change from baseline at Day 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scale severity score</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
    <description>Change from baseline at Day 14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analogue Scale(VAS) score</measure>
    <time_frame>Change from baseline at Day 14 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Seborrheic Dermatitis</condition>
  <arm_group>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 0.3%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 1.0%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream vehicle</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged between 19 and 65 years old

          -  Clinical diagnosis of seborrheic dermatitis in the facial area with Erythema severity
             ≥ 2 and Scaling severity ≥ 2

          -  IGE (Investigator's Global Evaluation) Score 2 or 3

        Exclusion Criteria:

          -  Patients with psoriasis, atopic dermatitis, facial acne, rosacea or perioral
             dermatitis

          -  Patients who have been infected with bacteria, fungi, virus and animal infectious
             disease on the facial area

          -  Patients who were administered topical antifungal agents, steroids, retinoids, or
             calcineurin suppressants for the treatment of seborrheic dermatitis within the last 2
             weeks

          -  Patients who were administered systemic antifungal agents, steroids, retinoids, or
             immunosuppressants for the treatment of seborrheic dermatitis within the last 4 weeks

          -  Patients who were administered local antibiotics for the treatment of seborrheic
             dermatitis within the last 4 weeks

          -  Pregnant women, breastfeeding women or women of childbearing potential or women who
             are planning a pregnancy during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BeomJoon Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Chungang University Hospital</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

